Patient reported outcomes in Triple Class Exposed, Relapsed/Refractory Multiple Myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): idecabtagene Vicleucel (ide-cel) versus standard regimens

被引:0
|
作者
Einsele, H. [1 ]
Delforge, M. [2 ]
Patel, K. [3 ]
Eliason, L. [4 ]
Dhanda, D. [4 ]
Shi, L. [5 ]
Guo, S. [5 ]
Marshall, T. [4 ]
Arnulf, B. [6 ]
Cavo, M. [7 ]
Nooka, A. [8 ]
Manier, S. [9 ]
Callander, N. [10 ]
Giralt, S. [11 ]
Ailawadhi, S. [12 ]
McKiver, Popa M. [4 ]
Cook, M. [13 ]
Rodriguez Otero, P. [14 ]
机构
[1] Uniklinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Bristol Myers Squibb, Princeton, NJ USA
[5] Evidera, Bethesda, MD USA
[6] Hop St Louis, Paris, France
[7] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
[8] Emory Univ, Winship Canc Inst, Atlanda, GA USA
[9] Ctr Hosp Univ Lille, Lille, France
[10] Univ Wisconsin Hlth, Madison, WI USA
[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[12] Mayo Clin, Jacksonville, FL 32224 USA
[13] Celgene Int Sarl, Boudry, Switzerland
[14] Clin Univ Navarra, Pamplona, Spain
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
V545
引用
收藏
页码:83 / 83
页数:1
相关论文
共 50 条
  • [1] Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)
    Giralt, Sergio
    Ailawadhi, Sikander
    Arnulf, Bertrand
    Patel, Krina
    Cavo, Michele
    Nooka, Ajay K.
    Manier, Salomon
    Callander, Natalie
    Costa, Luciano J.
    Vij, Ravi
    Bahlis, Nizar J.
    Moreau, Philippe
    Solomon, Scott R.
    Delforge, Michel
    Berdeja, Jesus
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Favre-Kontula, Linda
    Wu, Fan
    Piasecki, Julia
    Cook, Mark
    Rodriguez-Otero, Paula
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S527 - S528
  • [2] Idecabtagene vicleucel (Ide-cel) versus standard regimens in patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 a Phase 3 Randomized Controlled Trial (RCT)
    Scheid, C.
    Rodriguez, Otero P.
    Ailawadhi, S.
    Arnulf, B.
    Patel, K.
    Cavo, M.
    Nooka, A. K.
    Manier, S.
    Callander, N.
    Costa, L. J.
    Vij, R.
    Bahlis, N. J.
    Moreau, P.
    Solomon, S. R.
    Delforge, M.
    Berdeja, J.
    Truppel-Hartmann, A.
    Favre-Kontula, L.
    Wu, F.
    Piasecki, J.
    Cook, M.
    Giralt, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 79 - 80
  • [3] Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups
    Patel, Krina
    Rodriguez-Otero, Paula
    Manier, Salomon
    Baz, Rachid
    Raab, Mark-Steffen
    Cavo, Michele
    Callander, Natalie
    Costa, Luciano J.
    Moreau, Phillippe
    Solomon, Scott
    Chen, Christine
    Raje, Noopur
    Scheid, Christoph
    Delforge, Michel
    Larsen, Jeremy
    Pabst, Thomas
    Suzuki, Kenshi
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Piasecki, Julia
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Giralt, Sergio
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S498
  • [4] Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis
    Patel, Krina
    Rodriguez-Otero, Paula
    Manier, Salomon
    Baz, Rachid
    Raab, Marc
    Cavo, Michele
    Callander, Natalie
    Costa, Luciano
    Moreau, Philippe
    Solomon, Scott
    Chen, Christine
    Raje, Noopur
    Scheid, Christoph
    Delforge, Michel
    Larsen, Jeremy
    Pabst, Thomas Mueller
    Suzuki, Kenshi
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Piasecki, Julia
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Giralt, Sergio
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S56 - S57
  • [5] Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients
    Patel, Krina K.
    Rodriguez-Otero, Paula
    Nooka, Ajay K.
    Callander, Natalie S.
    Solomon, Scott R.
    Baz, Rachid
    Sborov, Douglas W.
    Gergis, Usama
    Badros, Ashraf Z.
    Giralt, Sergio A.
    Pearse, Roger
    Abonour, Rafat
    Siegel, David S.
    Larson, Sarah M.
    Munshi, Nikhil C.
    Truppel-Hartmann, Anna
    Bhatnagar, Rashmi
    Wu, Fan
    Piasecki, Julia
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Mckiver, Mihaela Popa
    Jagannath, Sundar
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S551 - S552
  • [6] Idecabtagene Vicleucel (ide-cel) versus Standard (std) Regimens in Patients (pts) with Triple-class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
    Scheid, Christoph
    Rodriguez-Otero, Paula
    Ailawadhi, Sikander
    Arnulf, Bertrand
    Patel, Krina
    Cavo, Michele
    Nooka, Ajay K.
    Manier, Salomon
    Callander, Natalie
    Costa, Luciano J.
    Vij, Ravi
    Bahlis, Nizar J.
    Moreau, Philippe
    Solomon, Scott R.
    Abrahamsen, Ingerid Weum
    Baz, Rachid
    Broijl, Annemiek
    Chen, Christine
    Jagannath, Sundar
    Raje, Noopur
    Delforge, Michel
    Benjamin, Reuben
    Pabst, Thomas
    Iida, Shinsuke
    Berdeja, Jesus
    Truppel-Hartmann, Anna
    Bhatnagar, Rashmi
    Wu, Fan
    Piasecki, Julia
    Eliason, Laurie
    Dhanda, Devender
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Mckiver, Mihaela Popa
    Giralt, Sergio
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 247 - 248
  • [7] Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
    Rodriguez Otero, Paula
    Ailawadhi, Sikander
    Arnulf, Bertrand
    Patel, Krina K.
    Cavo, Michele
    Nooka, Ajay K.
    Manier, Salomon
    Callander, Natalie S.
    Costa, Luciano
    Vij, Ravi
    Bahlis, Nizar J.
    Moreau, Philippe
    Solomon, Scott R.
    Abrahamsen, Ingerid Weum
    Baz, Rachid
    Broijl, Annemiek
    Chen, Christine
    Jagannath, Sundar
    Raje, Noopur S.
    Scheid, Christof
    Delforge, Michel
    Benjamin, Reuben
    Pabst, Thomas
    Iida, Shinsuke
    Berdeja, Jesus G.
    Truppel-Hartmann, Anna
    Bhatnagar, Rashmi
    Wu, Fan
    Piasecki, Julia
    Eliason, Laurie
    Dhanda, Devender
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Popa-McKiver, Mihaela
    Giralt, Sergio A.
    BLOOD, 2023, 142
  • [8] Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy
    Einsele, Hermann
    Rodriguez-Otero, Paula
    Arnulf, Bertrand
    Patel, Krina
    Manier, Salomon
    Costa, Luciano
    Bahlis, Nizar
    Broijl, Annemiek
    Chen, Christine
    Abrahamsen, Ingerid Weum
    Delforge, Michel
    Gergis, Usama
    Raab, Marc
    Singhal, Seema
    Abonour, Rafat
    Truppel-Hartmann, Anna
    Bhatnagar, Rashmi
    Felten, Jasper
    Caia, Andrea
    Wu, Fan
    Piasecki, Julia
    Cook, Mark
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S37 - S37
  • [9] Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy
    Manier, Salomon
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Einsele, Hermann
    Bahlis, Nizar
    Munshi, Nikhil
    Ailawadhi, Sikander
    Arnulf, Bertrand
    Nooka, Ajay
    Vij, Ravi
    Abrahamsen, Ingerid Weum
    Broijl, Annemiek
    Jagannath, Sundar
    Benjamin, Reuben
    Gergis, Usama
    Sborov, Douglas
    Iida, Shinsuke
    Truppel-Hartmann, Anna
    Yang, Zhihong
    Bhatnagar, Rashmi
    Piasecki, Julia
    Felten, Jasper
    Caia, Andrea
    Cook, Mark
    Baz, Rachid
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S50 - S51
  • [10] Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients (pts) receiving bridging therapy
    Einsele, Hermann
    Rodriguez-Otero, Paula
    Arnulf, Bertrand
    Patel, Krina
    Manier, Salomon
    Costa, Luciano J.
    Bahlis, Nizar J.
    Broijl, Annemiek
    Chen, Christine
    Abrahamsen, Ingerid Weum
    Delforge, Michel
    Gergis, Usama
    Raab, Marc S.
    Singhal, Seema
    Abonour, Rafat
    Truppel-Hartmann, Anna
    Bhatnagar, Rashmi
    Felten, Jasper
    Caia, Andrea
    Wu, Fan
    Piasecki, Julia
    Cook, Mark
    Ailawadhi, Sikander
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 141 - 142